Award Data

N/A

DESCRIPTION (provided by applicant): The partial opioid agonist buprenorphine, is expected to be approved by the FDA in the very near future for the treatment of opioid-dependence and will be available via physician prescription, enabling a greatly needed expansion of access to opioid treatment services. However, physicians, because of considerable demands on their time, will likely be unable to p ...

The Architecture Analysis and Design Language (AADL) is an SAE standard language for describing the software and hardware architecture of performance-critical real-time systems. In addition, the AADL standard allows the definition of annexes, i.e., formal extensions to the standard language to enhance the design specifications of hardware or software components. We propose to leverage the AADL la ...

DESCRIPTION (provided by investigator): The medication dispensing and monitoring system, MD 2, has been shown in preliminary studies to support a medication compliance rate of 98.5% The MD 2 was developed by Interactive Medical Developments LC to address issues of medicine non-compliance and the negative impact non-compliance has on the health and well being of the patient and the frustration of c ...

DESCRIPTION (provided by applicant): The long-term goal of the collaboration between the USC and Southern Sun BioSystems is to create a plant breeding and remediation technology-development center which would supply hardware, protocols for breeding-selection and mass production of elite plants for nurseries and remediation businesses, with licensing and tracking mechanisms for protecting intellect ...

DESCRIPTION (provided by applicant): Phase I The current proposal describes the selection of an aptamer that recognizes the drug PD173955, which is one of large family of substituted pyrido[2,3-d]pyrimidine inhibitors of tyrosine protein kinases. An aptamer is a single stranded nucleic acid that acts like an antibody but that can be expressed and function inside cells. The PD173955 RNA aptamer wi ...

DESCRIPTION (provided by applicant): Phase I funding for this project supported successful studies that were aimed at demonstrating the feasibility of developing an easy to use, global test in the arena of clinical hemostasis that would be sensitive to antithrombotic drugs, bleeding disorders and thrombotic pathologies. This test comprises a measurement of the rate of thrombin generation and/or to ...

DESCRIPTION (provided by applicant): This program will demonstrate the potential for commercial success of a novel approach for tracking and displaying the position and orientation of instruments in image-guided cancer interventions. Prototype systems will be demonstrated in selected pancreatic procedures in human subjects. New clinical applications will be examined and commercialization will beg ...

We propose to develop a novel hybrid circuit approach combining CMOS and two terminal crosspoint nanodevices with a novel interface consisting of an array of pins with nanometer scale tips. Our CMOL approach will allow the fabrication of ultra-dense integrated circuits (up to 10^12 active devices per cm2) for advanced computing (up to 10^20 operation per cm2 per second), information storage and se ...

DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 21,810 cases of primary malignant brain tumor will be reported in the US in 2008. The ACS also estimates that 13,070 deaths will occur due to these diseases in this year. This Phase II STTR program advocates the development of drugs for primary CNS cancers from the schweinfurthin family of natural products. ...